Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. - Wikidata - awgldk - TriplyDB

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.

http://www.wikidata.org/entity/Q33345746

about

Temozolomide for children and adolescents with diffuse intrinsic pontine glioma DIPG in Children - What Can We Learn from the Past?Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.Advances in treatment of pediatric brain tumors Temozolomide in paediatric high-grade glioma: a key for combination therapy?Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.Temozolomide: a milestone in neuro-oncology and beyond?A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report Novel drugs in pediatric gliomas.Pediatric high-grade glioma: biologically and clinically in need of new thinking Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.Management of diffuse pontine gliomas in children: recent developments.Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.Management of high-grade gliomas in the pediatric patient: Past, present, and future.The role of funding and policies on innovation in cancer drug development.Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.Pediatric CNS tumors: current treatment and future directions.Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.Pediatric brain tumors: current treatment strategies and future therapeutic approaches Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Grade Gliomas in Children and Adolescents.Combination of Endothelial-Monocyte-Activating Polypeptide-II with Temozolomide Suppress Malignant Biological Behaviors of Human Glioblastoma Stem Cells via miR-590-3p/MACC1 Inhibiting PI3K/AKT/mTOR Signal Pathway.Treatment of posterior fossa tumors in children.Paediatric and adult malignant glioma: close relatives or distant cousins?Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.

P2860

Q24200164-FC4375EF-BF7C-492F-BD3B-DBC9E6F84246 Q26777843-2F707135-E273-4759-874D-F7EC5A844CA5 Q26785952-349D5FFB-47AE-4677-ADF8-7F9752D5B450 Q30679553-6BC49BE1-4A06-4C1C-9D14-DFAEDF69ABBF Q33237311-DD6972B6-AB7E-4A28-9C52-50562F8F2EA2 Q33361765-D2BD18FF-44E0-41F0-B0B7-44D3177A5E43 Q33368246-F166CE55-94D1-49E3-813D-CCD56178D2E8 Q33372340-5783439D-BDA7-4E36-9539-5867DD2483ED Q33379701-BB291DA9-49CD-4313-9EA6-E7427E93AD49 Q33391731-15E8F217-5761-498A-B899-8DE61407430A Q33392585-7AC6BC41-6812-461C-8BB4-8BAD94CD0813 Q33406813-AF9325E9-5791-4EC9-8195-FF724D0941E2 Q33407691-FC352288-211A-4C38-8AD4-07D942879B4F Q33409117-011B2343-DFBD-4C2D-9A6D-F27662731E12 Q33415790-B1B15C38-B379-44E4-A6EC-E989738F4292 Q33685551-929DA0F9-D677-4CA0-89C7-3AE9B8A0BA00 Q33777868-7337E503-1ABC-493A-A76D-FB031C9D9E29 Q33990959-77A49DE7-BD5C-422D-BDC3-7095C6DE82B6 Q34287713-1CEE0766-31C4-43C2-BB0C-D322FD7219E0 Q34347540-E131701F-94EC-4428-9798-916CED44A3D9 Q34359662-231A4CB6-A154-4123-8990-23EC0B09EBEE Q34468816-7C2EE934-ABA5-45BB-85C0-0028DF49B94E Q34495470-BB585EE5-08F5-437D-AA6A-96A047C6BBE3 Q34541456-44517868-115D-4B3B-8EBB-B3D1BB4C0D53 Q34722440-6CA6D128-55C2-4165-8DB9-4B21C159BD53 Q35206259-89E49636-0F17-44BE-A184-C21BB3C2CC2D Q35602147-8C6DBCA8-B9E2-4FB5-8B06-3341597F9721 Q35769714-708765A3-BE68-4FE4-A886-91615EA8656D Q36455403-7EB24E72-0155-4DD3-AAB6-F25ADB039FC2 Q36902043-2B2F1D49-A277-4EAB-87C9-A284E930F479 Q37069238-BC54EC76-4609-4B81-AE4D-97E2B70856CF Q37151985-A4FBDA9B-CC56-4FB6-9C78-EB7433D72252 Q37533670-BBCC30CE-5EE3-4EFA-BCA8-30173D187B39 Q37564201-0E05B3FE-8A51-4D50-A5DF-A07AEEB99850 Q37570127-41E5C056-FB94-4ED9-96A1-0B21C9309901 Q37694434-93E63466-44AC-43C2-9A0E-38FC2F4E786C Q37724213-BD4DFE7D-2774-4DEB-9A8E-B53003E38C5C Q38013990-783C4F31-1BCF-4C27-9991-C6F647865DB8 Q38074880-5EE7EC10-80E9-4A89-BDCD-0669BB729A6F Q38086448-17AD5378-0027-4C6D-9CAC-62B71FDA27B6

P2860

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.

http://www.wikidata.org/entity/Q33345746

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Temozolomide in malignant glio ...... ric Oncology Intergroup Study.

@ast

Temozolomide in malignant glio ...... ric Oncology Intergroup Study.

@en

type

label

Temozolomide in malignant glio ...... ric Oncology Intergroup Study.

@ast

Temozolomide in malignant glio ...... ric Oncology Intergroup Study.

@en

prefLabel

Temozolomide in malignant glio ...... ric Oncology Intergroup Study.

@ast

Temozolomide in malignant glio ...... ric Oncology Intergroup Study.

@en

P1433

Q33345746-9BC823A8-79E5-4419-BF4B-0BD6E17B052C

P1476

Q33345746-7CC77297-7CB2-4F4A-94B8-542F0FC0A577

P2093

Q33345746-00DFBF4C-6086-45E2-A171-C61397AE6C77

Q33345746-0199DC9F-2A1C-4A92-BC6F-5F2355E16F9A

Q33345746-022B2432-1D7A-44B8-A7A4-F1F676856AA3

Q33345746-2B4A7F63-2589-4FF2-96E5-D4BBA15032E5

Q33345746-40CBDD9B-5ECC-4A83-823D-412C4C5221FB

Q33345746-6F27102A-A6FA-449F-98B8-F299C2EB8A58

Q33345746-72D32BCF-4132-4AA8-A99C-93D08093119C

Q33345746-A1302FB6-DFCD-4EA2-AE79-20D80172B2EF

Q33345746-A5E87FDF-3BD6-4D2C-9A0C-095ACACC6A0D

Q33345746-BE1F6F76-71C7-4EB6-B8F2-C2E56FC51257

P304

Q33345746-9169A729-445D-485B-BAFD-47097CB4CAE6

P31

Q33345746-D1ECD2F7-E891-4B0E-9E9D-93FC3D82AAE8

P356

Q33345746-91C9924A-0E89-4E3D-931A-C603C943398C

P407

Q33345746-7726639C-8FE9-4560-A55C-04223716EB89

P433

Q33345746-8D4D42C4-562D-4A6C-A242-61B8487C3DF5

P478

Q33345746-5E9E7F4B-AFC4-435E-813E-42BDD058C4E9

P50

Q33345746-093EA68D-996C-4D8D-AC8A-A8FAA9A1D92B

Q33345746-31879F08-50BD-4E97-827A-DD696302EB0C

P577

Q33345746-9EA7AF5E-C95C-4F1B-A839-7DEE460A247B

P698

Q33345746-A5038BC4-597F-47FF-AEF3-5E4C1D262B9C

P356

JCO.2002.08.141

P1433

Journal of Clinical Oncology

P1476

Temozolomide in malignant glio ...... ric Oncology Intergroup Study.

@en

P2093

A D J Pearson

http://www.w3.org/2001/XMLSchema#string

A Jouvet

http://www.w3.org/2001/XMLSchema#string

D Couanet

http://www.w3.org/2001/XMLSchema#string

D Frappaz

http://www.w3.org/2001/XMLSchema#string

G Vassal

http://www.w3.org/2001/XMLSchema#string

K Robson

http://www.w3.org/2001/XMLSchema#string

L S Lashford

http://www.w3.org/2001/XMLSchema#string

M Dugan

http://www.w3.org/2001/XMLSchema#string

P D Griffiths

http://www.w3.org/2001/XMLSchema#string

P Thiesse

http://www.w3.org/2001/XMLSchema#string

P304

4684-4691

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2002.08.141

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12488414

http://www.w3.org/2001/XMLSchema#string